Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
Lung Cancer
Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint
The phase 3 study compared tiragolumab plus atezolizumab with placebo plus atezolizumab in adults with PD-L1 high locally advanced, unresectable or metastatic NSCLC.
Cancer Researchers Aren’t Reporting Quality of Life Outcomes Accurately
Quality of life outcomes were reported favorably for trials that showed no improvement in quality of life.
New Cancer Diagnosis Linked to Increased Risk of Cardiovascular Death
A new cancer diagnosis is independently associated with a higher risk of cardiovascular death, stroke, heart failure, and pulmonary embolism.
FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC
Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.
Nearly 1 in 10 Cancer Patients May Not Receive Guideline-Concordant Care
The highest rate of non-concordant care was seen in patients with cervical cancer.
1 in 5 Cancer Patients on Phase 3 Trials Use Complementary Medicine
The most common complementary medicines were herbal/natural products, dietary supplements, fish oils, glucosamine, and homeopathic medicines.
Adagrasib Under Review for Previously Treated KRAS G12C-Mutated NSCLC
The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.
Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC
A PDUFA target date of November 24, 2022 has been set for the application.
Heart Failure Tied to Increased Risk of Cancers, Cancer-Related Mortality
The excess risk of cancer appeared to be associated with the severity of heart failure.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...